Rucaparib
Infiltrating Bladder Urothelial Carcinoma
Explore 15 assets in Infiltrating Bladder Urothelial Carcinoma →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
pharmaand GmbH
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03397394CT.gov Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Infiltrating Bladder Urothelial Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rucaparib (this asset) | pharmaand GmbH | P2 | CCC · 53 |
| Pembrolizumab | Fred Hutchinson Cancer Center | P2/3 | B |
| Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) | Fred Hutchinson Cancer Center | P2/3 | B |
| Nivolumab | National Cancer Institute (NCI) | P2/3 | B |
| Relatlimab | National Cancer Institute (NCI) | P2/3 | B |
| Cis-Diamminedichloroplatinum Ii | Vasgene Therapeutics, Inc | P2/3 | B |
| Recombinant Ephb4-Hsa Fusion Protein | Vasgene Therapeutics, Inc | P2/3 | CCC |
| Cabozantinib | National Cancer Institute (NCI) | P2 | CCC |
| Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 | National Cancer Institute (NCI) | P2 | CCC |
+7 more in the Infiltrating Bladder Urothelial Carcinoma cohort
Other indications for Rucaparib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Peritoneum Cancer | — | P3 | BB · 66 |
| Ovarian Cancer | — | P3 | B · 61 |
| Ovarian Carcinoma | — | P3 | B · 61 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- PembrolizumabFred Hutchinson Cancer CenterB
- Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)Fred Hutchinson Cancer CenterB
- NivolumabNational Cancer Institute (NCI)B
- RelatlimabNational Cancer Institute (NCI)B
- Cis-Diamminedichloroplatinum IiVasgene Therapeutics, IncB
Citation
Floatz Terminal. Rucaparib in Infiltrating Bladder Urothelial Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/rucaparib-infiltrating-bladder-urothelial-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →